Compare DexCom, Inc. (DXCM) vs iShares MSCI Australia ETF (EWA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs iShares MSCI Australia ETF — how do they compare? DexCom, Inc. trades at $90.49 (market cap $33.79B), while iShares MSCI Australia ETF trades at $29.88. The key difference: DexCom, Inc. is trading nearer its 52-week high, iShares MSCI Australia ETF nearer its low. Which is the better fit depends on your goals.
| DXCM | EWA | |
|---|---|---|
Market Cap | $33.79B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $89.53 | $30.41 |
52-Week Low | $54.84 | $24.95 |
Enterprise Value | $33.24B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $90.23, up 2.94% today and near its 52-week high, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating EPS estimates with $0.70 versus $0.61 expected, and raised full-year guidance. Revenue growth remains robust at 13% year-over-year, supported by G7 system adoption and international expansion. Profit margins improved, with net income margin reaching 20.12% in 2025. Analyst sentiment is overwhelmingly positive, with 80% buy ratings.
The outlook for DXCM is favorable due to sustained demand for continuous glucose monitors and strategic initiatives like 'Road to 100'. Key risks include competitive pressures, regulatory scrutiny, and valuation multiples above industry averages. The stock's current price is slightly above the consensus target of $88.65, suggesting near-term consolidation may occur before further upside.
EWA trades at $29.875, down 0.58% today, with a bullish technical signal from moving averages and neutral oscillators. The stock shows strong momentum with ADX readings above 40, indicating a trending market. Recent corporate actions include a dividend scheduled for June 2026. Key support and resistance cluster around $30, suggesting a critical price zone for near-term direction.
Outlook remains cautiously optimistic given technical strength, but fundamental data is unavailable for valuation assessment. Risks include reliance on Australian economic conditions and market volatility. Investors should await updated financials to gauge intrinsic value and growth prospects amid evolving macroeconomic factors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About iShares MSCI Australia ETF
EWA tracks the MSCI Australia Index, providing broad exposure to large and mid-cap companies in the Australian equity market. It is structurally dominated by the financial and materials sectors, serving as a key instrument for investors seeking a single-country view of Australia's resource-rich and stable economy.
Read more on EWA →
